Wednesdays at Sheppard Pratt: Diagnostic and Therapeutic Challenges in Early-Onset Bipolar Disorder
Sheppard Pratt Health System is dedicated to improving quality of life through mental health, special education and addiction services for children, adolescents, adults and other adults. Our patient-centered treatment approach combined with our legacy of clinical excellence, sets us apart from other health systems on both a local and national level. We have been ranked among the nation's top psychiatric hospitals for 24 consecutive years by U.S. News & World Report. Founded in 1853 by philanthropist Moses Sheppard. Sheppard Pratt Health system still abides by its Quaker traditions and values.
Sheppard Pratt Health System's Professional Education Programs is pleased to provide the Wednesdays at Sheppard Pratt free of charge as a public service to the mental health community. Your tax deductible donations will help maintain the outstanding quality of this service. Please send your contributions to:
Sheppard Pratt Professional Education Programs
Wednesdays Lecture Fund
6501 N. Charles Street, Baltimore, MD 21204
Professional Education Programs: 410-938-4593
The Conference Center at Sheppard Pratt: 410-938-3900
This activity is intended for phsycians, nurses, psychologists, social workers, counselors and mental health professionals.
Define the illness characteristics of pediatric bipolar disorder.
Identify evidence-based treatments for the acute and maintenance treatment of bipolar mania and bipolar depression in youth.
Compare different strategies to monitor and manage adverse effects associated with medications used to treat bipolar disorder in youth.
From the Baltimore Beltway, take exit 25, Charles Street. Proceed south on Charles Street for approximately 2.5 miles. The entrance to Sheppard Pratt will be on your left, just past the stone gatehouse. You will be on Gatehouse Drive. Take the first left onto Conference Center Drive. Turn left to the parking area directly in front of the Conference Center.
Christoph Correll, is Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA, as well as head of the department of child and adolescent psychiatry at the Charité University, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City.
Professor Correll’s research and clinical work focus on the identification, characterisation and treatment of adults and youth with severe psychiatric disorders, including the prodrome, first episode, multi-episode and refractory illness phase of psychotic and mood disorders. He further focuses on psychopharmacology, comparative effectiveness, and the risk–benefit evaluation of psychotropic medications.
Professor Correll has authored or co-authored over 500 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received over 40 national and international research awards and fellowships for his work. Since 2014, the year of inception of this metric, he has been listed every year by Thomson Reuters as one of “the most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.
Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers and speakers have been asked to disclose any relationship he /she or their spouse/partner has with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt Health System, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.
Christoph U. Correll, M.D. reports receiving payment for honoraria, consultancy or as an advisor for Alkermes, Allergan, Gerson, Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Neurocrine, Otsuka, Pfizer, ROVI, Sunovion, Takeda and Teva during the past 12 months. He will discuss medications and off-label uses of lamotrigine, valproate, oxcarbazepine, lamotrigine, lurasidone and ziprasidone for pediatric bipolar disorder in this presentation.
Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months: Ellen Mongan, M.D., Caroline Cahn, LCSW-C, Tom Flis, LCPC, Faith Dickerson, Ph.D., Robert Roca, M.D., Drew Pate, M.D., Meena Vimalananda, M.D., Briana Riemer, M.D. Ernestine Crosby, APRN, Darby Subotich, RN, MSN, Rick Wallace, RN, MSN, Jacqueline Williams-Porter, RN, MBA, Jennifer Tornabene, and Bonnie Katz.
Physician Statement: Sheppard Pratt Health System is accredited by The Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. Sheppard Pratt Health System designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Statement: Sheppard Pratt Health System is an approved provider of continuing nursing education by Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity is approved for 1.0 contact hours for nurses.
Psychologist Statement: Sheppard Pratt Health System is authorized by the State Board of Examiners of Psychologists as a sponsor of continuing education. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. Sheppard Pratt Health System designates this educational activity for a maximum of 1.0 CEU hours for Psychologists. Psychologists should claim credit commensurate with the extent of their participation in the activity.
Social Worker Statement: Sheppard Pratt Health System is authorized by the Board of Social Work Examiners of Maryland to offer continuing education for Social Workers. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity is approved for 1.0 CEU contact hours in Category 1 credits for Social Workers.
Counselor Statement: Sheppard Pratt Health System has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5098. Programs that do not qualify for NBCC credit are clearly identified. Sheppard Pratt Health System is solely responsible for all aspects of the program. This activity is available for 1.0 NBCC clock hours.
- 1.00 ACEP NBCC clock hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Category I credits for Social Workers
- 1.00 Psychologists
- 1.00 Participation